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Abstract 
Introduction: GAP system have proven to be an easy tool for predicting disease stages and 
survival in IPF patients.  
Objective: To validate mortality risk as determined by the GAP system in a real-life multicenter 
IPF population treated with pirfenidone. 
Methods:The study included patients who received pirfenidone for at least 6 months. The GAP 
calculator and the GAP index were determined. The primary outcome was all-cause mortality. The 
prognostic accuracy of the GAP system was evaluated with respect to calibration and 
discrimination. 
Results and Conclusion: 68 IPF patients were enrolled in the study. The median follow-up was 2.4 
years (range 0.1-7.4 years). A total of 22 deaths as first event (32%) and of 10 lung transplantation 
(15%) were recorded. The cumulative incidence of mortality at 1, 2, and 3 years was 10.4%, 22.4%, 
and 38.4%, respectively. The differences between the predicted and observed  mortality were not 
significant for the GAP index while the observed mortality become comparable to that predicted by 
the GAP calculator only in the third year of follow up.  The C-index for the GAP index was 0.74 
(95% CI 0.57-0.93) while the C-statistic value for the GAP calculator was 0.77 (95% CI 0.59-0.95).  
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 This is the first study that investigate the reliability of the GAP system as a predictive tool in the 
era of antifibrotic therapies in a national real life IPF population. In our cohort the GAP system 
showed a good discrimination index. Additional studies would be evaluable to determine the impact 
of treatment on model performance.  
 
Keywords: mortality, survival, idiopathic pulmonary fibrosis, anti-fibrotic therapies, prognosis, 
staging. 
 
Main text  
Introduction 
In recent years, there has been a growing interest in scores that allow to determine the severity of 
patients with idiopathic pulmonary fibrosis (IPF), to assess the prognosis, to evaluate possible 
treatment options including timing to transplant and to standardize cohorts of patients in controlled 
clinical studies (1-6). Among a number of different methods, the GAP index and the GAP 
calculator for the GAP Risk Assessment System (GAP system) have proven to be the most easy and 
applicable tool in the current clinical practice (1); however, there are still only few studies that have 
assessed their applicability and usefulness in daily practice. Furthermore, ethnicity has been 
reported as a factor that can  influence the reliability of these two scoring systems, as demonstrated 
by the  Korean and Japanese experiences (7, 8). Indeed, up until now most of the data have been 
derived from American studies (1). Finally, to our knowledge, there are still very few clinical trials 
that have evaluated the applicability of the GAP system in the era of antifibrotic therapies (9, 10).  
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We herewith report an Italian national multicentre experience aimed to validate the predictive value 
of the risk of death determined by these two indicators in a retrospective analysis of a cohort of 
patients with IPF who received pirfenidone, the first antifibrotic drug marketed for the treatment of 
this disease. 
 
Materials and methods 
Patient population and study design. 
The study sample herewith considered is in part derived from a previous retrospective observational 
study carried out on continuous patients diagnosed with mild, moderate and severe IPF and treated 
with pirfenidone in the period between April  2011 and January 2013 (11); the study involved 12 
interstitial lung disease centers across Italy that joined the European Named Patient Access Program 
(NPP). The Company that was involved in the development and marketing of pirfenidone in Europe 
has supported this program: InterMune Inc. has in fact allowed qualified physicians to make the 
newly approved pirfenidone available to their IPF patients, provided that pre-specified medical 
criteria and conditions were met, before it was commercially available within a given European 
country. The drug was made available to patients free of charge. Patients who had received steroids, 
azathioprine, or N-acetylcysteine (NAC) before pirfenidone therapy initiation were not excluded 
from the analysis; azathioprine and NAC were stopped before treatment with pirfenidone, low dose 
steroids (<15 mg/day) were continued in some patients. Data of patients who had been enrolled in 
the CAPACITY trials and subsequently entered the NPP program were also included (11).  
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All patients who received at least 6 months of treatment with the new antifibrotic drug and who had 
pulmonary function data available at six months after pirfenidone initiation where included in the 
study and followed up. The diagnosis of IPF was performed with criteria of the statement of 
ATS/ERS/JRS/ALT in 2011 (12). 
The primary outcome was all-cause mortality ascertained. Lung transplantation was treated as a 
competing risk. 
The GAP Risk Assessment System (1), which combines commonly measured clinical (age and 
gender) and physiologic variables, forced vital capacity  (FVC) and capacity of the lung for carbon 
monoxide (DLCO), was used as predictor variable. The individual risk calculator (the GAP 
calculator) and the staging system (the GAP index), were evaluated after six months of pirfenidone 
therapy.  The formula of the GAP calculator is described in the Appendix (online material). 
Purpose of this study was the validation of the GAP system evaluated after six months of 
pirfenidone therapy in predicting the subsequent risk of death in an Italian population of patients 
affected by IPF.  
This study was approved by the San Giuseppe Hospital Ethical Committee (protocol number 27/13) 
and patient’s confidentiality was maintained. 
Statistical analysis 
Patients were followed up after six months of pirfenidone treatment. Vital status was ascertained by 
each participating center until July 2015.  
Mortality risk was estimated in terms of  cumulative incidence failure (CIF) taking into account 
lung transplantation as a competing cause of event. The Gray’s test was used to assess cumulative 
incidence differences between groups. 
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Using the GAP Risk Assessment System (1) the predicted 1-, 2- and 3-yr risk of death after six 
months of pirfenidone treatment has been calculated for each patient in the cohort. The GAP system 
consists in a point scoring stage model (GAP index) and a continuous calculator (GAP calculator) 
derived from variables available at study entry (clinical visit at six months after pirfenidone 
treatment).   
 
The prognostic accuracy of the GAP system was evaluated with respect to discrimination and 
calibration. 
 
Discrimination was measured by the Harrell’s concordance statistics (c-index), which is the 
probability that given two randomly selected patients, the survival time predicted by the GAP 
system is greater for the subject who survived longer. A value of 1 denotes perfect concordance, 
while a value of 0.5 is no better than chance.  
 
Calibration was evaluated by a visual inspection of the plot comparing the 1-yr, 2-yr and 3-yr 
average mortality predicted by the GAP model with cumulative incidence of mortality  observed in 
groups defined by the GAP stage (i.e. stage I, stage II and stage III). The Hosmer-Lemeshow test 
was used to formally compare predicted and observed risks.  
 
All statistical analyses were performed with SAS software, version 9.3 (SAS Institute Inc., Cary, 
North Carolina) and R-software  (R Foundation for Statistical Computing, Vienna, Austria).  A p-
value<0.05 was considered statistically significant. All reported p-values are two sided. 
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Results 
Sixty eight IPF patients treated for at least 6 months with pirfenidone were studied. The 
characteristics of the sample are shown in Table 1. 
Pulmonary function profile and stratification of the population based on GAP severity index, as 
well as GAP calculator, of studied sample at six months after pirfenidone treatment is reported in 
Table 2.  
The median duration of follow-up time, which started from the sixth month of treatment,  was 2.4 
years (range 0.1-7.4 years). A total of 22 deaths as first event (32%) and of 10 lung transplantation 
(15%) occurred during follow up. The cumulative incidence of mortality  at 1, 2, and 3 years was 
respectively 10.4% (95% CI: 4.6%-19.2%), 22.4% (13.2%-33.0%), and 38.4% (95% CI 24.9%-
51.7%) (Fig. 1). 
Mortality risk was significantly different according to GAP index stage (Gray’s test p<0.0001). The 
cumulative incidence of mortality at 3 years was 14.8% (95% CI 1.7%-40.8%) for stage I,  36.9% 
(95% CI 20.0%-53.9%) for stage II and 80% (95% CI 32.6%-95.7%) for stage III (Fig. 2).  
The cumulative incidence of mortality observed among the study sample and that predicted by the 
GAP Risk Assessment System were reported in Table 3 separately by year of follow up and 
stratified by GAP stage. 
The risk of death predicted by the GAP system was compared with the observed mortality using 
calibration plots (Fig. 3 and 4).  
The observed cumulative incidence of mortality for stage I and for stage II  was lower while, for 
stage III was higher than mortality predicted by both the GAP index and the GAP calculator at each 
year of follow up. However, while the GAP index was quite precise in predicting mortality and the 
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differences between the predicted and observed risks were not significant (Hosmer-Lemeshow 
p=0.088, p=0.218 and p=0.778  at 1, 2, and 3 years, respectively), the observed mortality becomes 
comparable to that predicted by GAP calculator only in the third year of follow up (Hosmer-
Lemeshow p=0.014, p=0.019 and p=0.061  at 1, 2, and 3 years, respectively).  
The C index for the GAP index was 0.74 (95% CI 0.57-0.93) while the C statistic value for the 
GAP calculator was 0.77 (95% CI 0.59-0.95).  
The median difference of the GAP index before and after the administration of pirfenidone was 
equal to zero. 
 
Discussion  
This is the first study investigating the use of the GAP system, a validated tool to assess mortality 
risk, in the era of antifibrotic therapies in a national multicenter case series of real life patients with 
IPF. The use of a simple staging system is very important to properly plan the therapeutic actions 
and some important decisions, such as the timing for lung transplantation and in helping clinicians 
to more accurately counsel patients with IPF (1-6). Being able to assess the clinical course and 
response to therapy of individual IPF patients is still both an open issue and a major objective to be 
achieved. The difficulty stems from the fact that the course of the disease is extremely variable for 
each individual patient. Reliable prognostic indicators have therefore not yet been identified (9). 
Guidelines consider the variations of FVC as an indicator of response to therapy and as a prognostic 
indicator, but this topic is still subject to much debate (12-19). Some authors have found significant 
mortality also in patients with stable FVC (5) and it has recently been reported that a 10% decline in 
FVC during pirfenidone therapy does not necessarily represent a treatment failure. Indeed, patients 
who continue getting pirfenidone despite progression of the disease may not experience further 
decline of FVC (19). The GAP index and disease staging system has been proposed as a quick and 
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simple prognostic tool for estimating mortality risk in patients with IPF, while the GAP calculator is 
a tool to estimate individuals' risk (1). In this real-life study conducted in patients treated with 
pirfenidone, the GAP system proved to be a reliable tool to predict mortality at 3 years. It seemed 
less sensitive at 1 and 2 years. The observed cumulative incidence of mortality for stage I and II 
patients was lower than the mortality predicted by both the GAP index and the GAP calculator for 
all follow-up time points. On the contrary, it was higher for stage III patients. The GAP index was 
quite accurate in predicting mortality, and the differences between the predicted and observed 
mortality were not significant (Hosmer-Lemeshow p = 0.088, p = 0.218 and p = 0.778 at 1, 2, and 
3 years, respectively). However, the observed mortality became comparable to that predicted by the 
GAP calculator only in the third year of follow-up (Hosmer-Lemeshow p = 0.014, p = 0.019 and 
p = 0.061 at 1, 2, and 3 years, respectively).The discrimination ability of the GAP index and the 
GAP calculator in our study was slightly higher than those obtained both in the original article (1) 
and in the validation study among Korean patients (7) (c-index 0.74 vs 0.70 and 0.66 respectively 
for the GAP index; c-index 0.77 vs 0.69 and 0.68 respectively for the GAP calculator). 
Studies have shown that the use of pirfenidone reduces pulmonary function loss at all stages of the 
disease (patients with FVC > 80% were compared to patients with FVC ≤ 80% and patients in GAP 
I stage were compared to patients in GAP II and III stages) (9, 20); on the other hand, FVC is 
considered a surrogate endpoint of mortality (14-18). In our study, the observed mortality was 
lower than the expected mortality in the GAP I and II stages the first two years and higher in the 
GAP III stage. This could be attributed to the different prevalence and influence of comorbidities in 
the various patient groups. Comorbidities may represent an additional factor to be taken into 
account for the GAP system to have a clinical relevance as a prognostic tool. Comorbidities may 
add their effect to age, gender and pulmonary function thereby modifying the overall mortality. 
This could explain why the GAP system might not be fully applicable when considering patients 
coming from real-life studies, with different comorbidities compared to clinical trial patients, who 
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may have been selected based on exclusion criteria (21, 22). However, this remains a hypothesis as 
the presence of comorbidities has not yet been analyzed for our study. 
A pooled analysis of the data from phase III pirfenidone studies (CAPACITY and ASCEND) 
showed that pirfenidone significantly reduced all-cause mortality and IPF treatment-related 
mortality at 1 year (23). The reduction in mortality observed in GAP I and II stage patients could 
therefore be attributed to a greater effect of therapy in the first 2 years of treatment. The difference 
observed in GAP III stage patients may be unreliable because of the small number of individuals in 
this group of seriously ill patients. 
Our study has all the known limits and all the bias of a retrospective research, but it also possesses 
the strengths of real-life studies. The other major limitation of our study is the small number of 
patients. However, our work describes a population certainly representative of the disease in a 
major European nation. All Italian centers that were considered in the study had participated in the 
NPP program and represent the most important reference centers for diagnosis and treatment of 
interstitial diseases. The follow-up period was long enough and suitable (2.4 years) and the average 
survival  recorded was of 3.7 years from the time of diagnosis, in line with the IPF experience and 
comparable to the Korean series (7). However, differences emerge from the comparison of this 
latest study and our own data. While the Koreans have in fact found differences in the calculation of 
the 2-year mortality and particularly at the 3-year mark, we instead had the opposite experience: 
being the figure predicted at 3 years the closest to  real.  
Significant differences do however exist between the two studies: in 17.9% of Korean patients the 
diffusion value was missing, while we instead only considered patients for whom a complete set of 
data was available. Furthermore, we only assessed patients taking pirfenidone while the Korean trial 
did not specify what therapy patients were following. Most probably, being this a cohort studied 
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between 2005 and 2009 nobody was taking pirfenidone. Also in our experience the GAP system 
proves to be a good staging system able to discriminate well among the three different risk classes. 
The GAP system is a simple-to-use disease staging system. It has found more applications than the 
previously proposed prediction models, which so far have had little impact in the daily clinical 
practice. This might be due to their complexity, time-consuming character or because they were 
never validated (2-4, 24, 25). The difference between the predicted and observed variables in our 
study population suggests that there may have been important factors (e.g. nature of IPF treatment 
or comorbidities) that were not captured by the GAP model. Additional studies would be valuable 
to determine the impact of treatment on model performance. This study was the first to evaluate the 
GAP system in the era of antifibrotic therapies and analyze its reliability in a multicenter Italian 
real-life population of patients treated with pirfenidone for almost six-months.  Our results raise 
some concerns about the use of GAP system in the clinical practice that deserve further study.The 
GAP model showed a similar discrimination index in our study population compared to Ley et al. 
(1). However, the GAP calculator did not accurately predict the 1- and 2-year mortality in 
individual patients with IPF treated with pirfenidone. In our cohort, the GAP system was more 
accurate in predicting mortality than the GAP calculator. The re-assessment of the GAP system in 
the era of new therapies for IPF is an important topic: we hope we gave our small contribution to 
have begun to address this new frontier that will anyway require further validation studies. 
 
Acknowledgements: This research did not receive any specific grant from funding agencies in the 
public, commercial, or not-for-profit sectors. 
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Figure legend 
Figure 1. Cumulative incidence of mortality from study entry (6 months after pirfenidone 
initiation).  
Figure 2. Cumulative incidence of mortality by GAP index stage from study entry (6 months after  
pirfenidone initiation).  
Figure 3. GAP index calibration plots. The x-axis shows the 1-yr (A), 2-yr (B), and 3-yr (C) 
cumulative incidence of mortality as predicted by the GAP model, and the y-axis shows the 
observed mortality. Every point represents a GAP stage. The solid line represents perfect agreement 
between predicted and observed mortality. 
Figure 4.  GAP calculator calibration plots. The x-axis shows the 1-yr (A), 2-yr (B), and 3-yr (C) 
cumulative incidence of mortality as predicted by the GAP model, and the y-axis shows the 
observed mortality. Every point represents a GAP stage. The solid line represents perfect agreement 
between predicted and observed mortality 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1. Patients’ characteristics  (N=68) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Mean age: 69 years (SD: 7.9 years) 
** Mean time from diagnosis of IPF to initiation of treatment with pirfenidone: 2 years (SD: 1.9 years) 
 
 
 
 
Table 2. GAP index and GAP calculator of patients at study entry (six months after pirfenidone therapy)  (N=68) 
 
 Predictor N (%) Median, (Min-Max) 
G - Gender 
Female 16 (24)   
Male 52 (76)   
A - Age class 
≤60 7 (10)   
61-65 12 (18)   
>65 49 (72)   
Physiology 
FVC %      
>75 29 (43)   
50-75 35 (51)   
<50 4 (6)   
DLCO %      
>55 14 (21)   
36-55 30 (44)   
≤35 24 (35)   
 GAP index   4 (2-7) 
 
GAP Risk Assessment System 
Stage I (GAP index 0-3) 21 (31)   
Stage II (GAP index 4-5) 37 (54)   
Stage III (GAP index 6-8) 10 (15)   
 
GAP calculator  
1-yr mortality 
2-yr mortality 
3-yr mortality 
  
 
16.3 (4.4-35.5) 
31.9 (9.2-61.2) 
45.4 (14.1-77.6) 
 
 
Characteristic Levels N (%) 
Gender 
Female 16 (24) 
Male 52 (76) 
Age (years)* 
≤60 7 (10) 
61-65 12 (18) 
>65 49 (72) 
Smoking status 
Ex-smoker 50 (74) 
Non smoker 15 (22) 
Smoker 3 (4) 
Histological diagnosis 
No 49 (72) 
Yes 19 (28) 
 
Cortisone 
No 27 (40) 
Yes 41 (60) 
Azathioprine 
No 50 (74) 
Yes 18 (26) 
N-Acetylcysteine 
No 38 (56) 
Yes 30 (44) 
Time from diagnosis of IPF to 
start of pirfenidone therapy 
(years) ** 
< 1 22 (32) 
1-2 24 (35) 
>2 22 (32) 
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Table 3. Comparison of predicted and observed cumulative incidence of mortality. 
 
Year GAP stage Predicted by GAP index Predicted by GAP Calculator Observed  
1 I 5.6 8.4 0.0 
 II 16.2 17.2 5.5 
 III 39.2 25.8 50.0 
2 I 10.9 17.6 4.7 
 II 29.9 34.2 19.4 
 III 62.1 48.4 70.0 
3 I 16.3 28.3 14.8 
 II 42.1 51.2 36.9 
 III 76.8 67.8 80.0 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
